https://www.live-feeds.com/feed/merck-tops-quarterly-estimates-hikes-profit-outlook-as-new-keytruda-form-shows-strengthContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/merck-tops-quarterly-estimates-hikes-profit-outlook-as-new-keytruda-form-shows-strengthhttps://www.live-feeds.com/feed/merck-tops-quarterly-estimates-hikes-profit-outlook-as-new-keytruda-form-shows-strength#u166710Sun, 01 Nov 2026 04:17:15 +0000Merck exceeded third-quarter expectations and raised its profit guidance, driven by stronger-than-anticipated sales of immunotherapy Keytruda and its newer injectable form Keytruda Qlex. The company's non-GAAP profit was $2.49 per share, 19.3% above analysts' consensus estimates. Merck's revenue was $18.09 billion, up 4.7% year on year.Why it mattersMerck's performance is significant as it reflects the company's continued strength in oncology and animal health. The pharmaceutical industry is highly competitive, and Merck's ability to exceed expectations and raise